Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July.
As in the USA, abiraterone acetate is indicated for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have previously received treatment with a docetaxel-based chemotherapy regimen.
The availability of abiraterone acetate through national health services in nations like the UK and Germany may still take a while to negotiate. However, for those in most of Europe who have health insurance (or can just afford to pay for the drug themselves), it is now legal to prescribe abiraterone acetate as the first important new oral therapy for the treatment of advanced prostate cancer since the introduction of bicalutamide (Casodex) back in the mid-1990s.